Investigator initiated study: galantamine CR potential enhancement of attentional and executive function in non-demented patients with Parkinson's disease
Latest Information Update: 26 Feb 2009
Price :
$35 *
At a glance
- Drugs Galantamine (Primary)
- Indications Parkinson's disease
- Focus Pharmacodynamics; Therapeutic Use
- 01 Jan 2009 Pharmacodynamic results were published in the Journal of Neurology, Neurosurgery and Psychiatry.
- 01 Sep 2006 New trial record.